Literature DB >> 28182618

The Evolving Landscape of HIV Drug Resistance Diagnostics for Expanding Testing in Resource-Limited Settings.

Seth C Inzaule1, Ralph L Hamers1,2, Roger Paredes3, Chunfu Yang4, Rob Schuurman5, Tobias F Rinke de Wit1.   

Abstract

Global scale-up of antiretroviral treatment has dramatically changed the prospects of HIV/AIDS disease, rendering life-long chronic care and treatment a reality for millions of HIV-infected patients. Affordable technologies to monitor antiretroviral treatment are needed to ensure long-term durability of limited available drug regimens. HIV drug resistance tests can complement existing strategies in optimizing clinical decision-making for patients with treatment failure, in addition to facilitating population-based surveillance of HIV drug resistance. This review assesses the current landscape of HIV drug resistance technologies and discusses the strengths and limitations of existing assays available for expanding testing in resource-limited settings. These include sequencing-based assays (Sanger sequencing assays and nextgeneration sequencing), point mutation assays, and genotype-free data-based prediction systems. Sanger assays are currently considered the gold standard genotyping technology, though only available at a limited number of resource-limited setting reference and regional laboratories, but high capital and test costs have limited their wide expansion. Point mutation assays present opportunities for simplified laboratory assays, but HIV genetic variability, extensive codon redundancy at or near the mutation target sites with limited multiplexing capability have restricted their utility. Next-generation sequencing, despite high costs, may have potential to reduce the testing cost significantly through multiplexing in high-throughput facilities, although the level of bioinformatics expertise required for data analysis is currently still complex and expensive and lacks standardization. Web-based genotype-free prediction systems may provide enhanced antiretroviral treatment decision-making without the need for laboratory testing, but require further clinical field evaluation and implementation scientific research in resource-limited settings.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28182618

Source DB:  PubMed          Journal:  AIDS Rev        ISSN: 1139-6121            Impact factor:   2.500


  7 in total

Review 1.  Human Immunodeficiency Virus Resistance Testing Technologies and Their Applicability in Resource-Limited Settings of Africa.

Authors:  Idris Abdullahi Nasir; Anthony Uchenna Emeribe; Iduda Ojeamiren; Hafeez Aderinsayo Adekola
Journal:  Infect Dis (Auckl)       Date:  2017-12-19

2.  Genotyping performance evaluation of commercially available HIV-1 drug resistance test.

Authors:  Audu Rosemary; Onwuamah Chika; Okpokwu Jonathan; Imade Godwin; Odaibo Georgina; Okwuraiwe Azuka; Musa Zaidat; Chebu Philippe; Ezechi Oliver; Agbaji Oche; Olaleye David; Samuel Jay; Dalhatu Ibrahim; Ahmed Mukhtar; DeVos Joshua; Yang Chunfu; Raizes Elliot; Chaplin Beth; Kanki Phyllis; Idigbe Emmanuel
Journal:  PLoS One       Date:  2018-06-28       Impact factor: 3.240

3.  Challenges to the performance of current HIV diagnostic assays and the need for centralized specimen archives: a review of the Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA) repository.

Authors:  Shelley N Facente; Michael P Busch; Eduard Grebe; Christopher D Pilcher; Alex Welte; Brian Rice; Gary Murphy
Journal:  Gates Open Res       Date:  2019-07-23

4.  Point-of-Care Tests for HIV Drug Resistance Monitoring: Advances and Potentials.

Authors:  Rayeil J Chua; Rupert Capiña; Hezhao Ji
Journal:  Pathogens       Date:  2022-06-25

5.  Pretreatment drug resistance in a large countrywide Ethiopian HIV-1C cohort: a comparison of Sanger and high-throughput sequencing.

Authors:  Nigus Fikrie Telele; Amare Worku Kalu; Solomon Gebre-Selassie; Daniel Fekade; Samir Abdurahman; Gaetano Marrone; Ujjwal Neogi; Belete Tegbaru; Anders Sönnerborg
Journal:  Sci Rep       Date:  2018-05-15       Impact factor: 4.379

6.  Comparison of an in-house 'home-brew' and commercial ViroSeq integrase genotyping assays on HIV-1 subtype C samples.

Authors:  Kaelo K Seatla; Wonderful T Choga; Mompati Mogwele; Thabo Diphoko; Dorcas Maruapula; Lucy Mupfumi; Rosemary M Musonda; Christopher F Rowley; Ava Avalos; Ishmael Kasvosve; Sikhulile Moyo; Simani Gaseitsiwe
Journal:  PLoS One       Date:  2019-11-21       Impact factor: 3.240

Review 7.  HIV-1 Drug Resistance Genotyping in Resource Limited Settings: Current and Future Perspectives in Sequencing Technologies.

Authors:  Sontaga Manyana; Lilishia Gounder; Melendhran Pillay; Justen Manasa; Kogieleum Naidoo; Benjamin Chimukangara
Journal:  Viruses       Date:  2021-06-11       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.